Results 271 to 280 of about 259,467 (345)

Comparing Prehospital Time Among Pediatric Poisoning Patients in Rural and Urban Settings. [PDF]

West J Emerg Med
Phillips AT, Denning M, Long-Mills E, Tumin D, Parker-Cote J, Bryant K.   +5 more
europepmc   +1 more source

Lifileucel tumor‐infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors

Cancer Communications, EarlyView.
Harriet Kluger, Götz Ulrich Grigoleit, Sajeve Thomas, Evidio Domingo‐Musibay, Jason A Chesney, Miguel F Sanmamed, Theresa Medina, Mirjana Ziemer, Eric Whitman, Friedrich Graf Finckenstein, Brian Gastman, Jeffrey Chou, Xiao Wu, Giri Sulur, Rana Fiaz, Rongsu Qi, Amod A Sarnaik   +16 more
wiley   +1 more source

Relative Bioavailability, Food Effect, and Bioequivalence Studies to Assess a New Zanubrutinib 160‐mg Tablet: Results From 2 Phase 1 Studies in Healthy Volunteers

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Zanubrutinib is a next‐generation Bruton tyrosine kinase inhibitor approved for treating B‐cell malignancies. Two phase 1 studies evaluated a new 160‐mg zanubrutinib tablet versus 80‐mg capsules. In study BGB‐3111‐115 (n = 43), a randomized 3‐period crossover trial, relative bioavailability and food effects were assessed.
Bilal Tariq, Chester Lin, Vaibhav Mundra, Yang Gao, Dan Zhang, Ying C. Ou   +5 more
wiley   +1 more source

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First‐in‐Human Randomized, Double‐Blind, Placebo‐Controlled Single Ascending Dose Escalation Phase 1 Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective 5‐hydroxytryptamine 2C (5‐HT2C) superagonist in development for the treatment of seizures in developmental and epileptic encephalopathies (DEEs). This double‐blind, placebo‐controlled, single ascending dose (SAD) Phase 1 study aimed to assess the safety, tolerability, and pharmacokinetic (PK) and ...
Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R Srinivas, Randall Kaye   +6 more
wiley   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective superagonist of the 5‐hydroxytryptamine 2C (5‐HT2C) receptor currently in development for the treatment of seizures that arise from developmental and epileptic encephalopathies. This phase 1, double‐blind, placebo‐controlled multiple ascending dose (MAD) study assessed the safety, tolerability, and ...
Jonathan Williams, Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R. Srinivas, Randall Kaye   +7 more
wiley   +1 more source

CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention in the Million Veteran Program

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 loss‐of‐function (LOF) alleles decrease the antiplatelet effect of clopidogrel following percutaneous coronary intervention (PCI) in patients presenting with acute coronary syndrome (ACS). The impact of genotype in patients undergoing PCI for stable ischemic heart disease (SIHD) in real‐world populations is less clear.
Catherine Chanfreau‐Coffinier, Kevin A. Friede, Mary E. Plomondon, Kyung Min Lee, Zhenyu Lu, Tia Dinatale, Scott L. DuVall, Jason L. Vassy, Stephen W. Waldo, John H. Cleator, Thomas M. Maddox, Daniel J. Rader, Themistocles L. Assimes, Scott M. Damrauer, Philip S. Tsao, Kyong‐Mi Chang, Deepak Voora, Julie A. Lynch, Jay Giri, VA Million Veteran Program, Sony Tuteja   +20 more
wiley   +1 more source

Developing and integrating a destination decision support algorithm into an innovative electronic communication platform to improve injury care service coordination in Rwanda: the Rwanda912 study protocol. [PDF]

BMJ Open
Rwanda912 RIGHT Group.
europepmc   +1 more source

Advancing Early Clinical Trials: The Transformative Potential of Decentralized Designs and Digital Technologies in Phase 1 Clinical Trial

Clinical Pharmacology &Therapeutics, EarlyView.
A Phase 1, open‐label, single‐dose, fixed‐sequence crossover study utilizing a hybrid decentralized clinical trial (DCT) design with and without practice sessions for wearable devices and PK sampling was conducted in eight healthy participants. Using etrasimod, the study assessed the feasibility of conducting a Phase 1 hybrid DCT by the Pfizer Clinical
Bimal K. Malhotra, Josué Kunjom Mfopou, Isabelle Huyghe, Pascal Ryckmans, Nathalie Severs, Anna Plotka, Kim‐Claire Tabner, Malgorzata Anna Jennes, Anand Bhuvanendran Nair, Anna Colzi   +9 more
wiley   +1 more source

Resilience enhancement of an urban road network during traffic accidents by optimally dispatching rescue teams. [PDF]

PLoS One
Chen J, Ju Y, Zhu S, Liu X, Hu X.
europepmc   +1 more source

Patterns of emergency dispatch calls and their changes during the COVID-19 pandemic in Ulaanbaatar, Mongolia. [PDF]

BMC Emerg Med
Ganbat G, Kim A, Namnansuren B, Batbaatar S, Kim H.   +4 more
europepmc   +1 more source